KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Gains from Sales and Divestitures: 2018-2020

Historic Gains from Sales and Divestitures for Esperion Therapeutics (ESPR) over the last 2 years, with Jun 2020 value amounting to $53,587.

  • Esperion Therapeutics' Gains from Sales and Divestitures rose 427.95% to $53,587 in Q2 2020 from the same period last year, while for Jun 2020 it was $53,587, marking a year-over-year increase of 427.95%. This contributed to the annual value of $17,710 for FY2019, which is 415.27% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Gains from Sales and Divestitures of $53,587 as of Q2 2020, which was up 431.14% from $10,089 recorded in Q1 2020.
  • Over the past 5 years, Esperion Therapeutics' Gains from Sales and Divestitures peaked at $53,587 during Q2 2020, and registered a low of $1,562 during Q1 2018.
  • In the last 3 years, Esperion Therapeutics' Gains from Sales and Divestitures had a median value of $6,763 in 2018 and averaged $11,851.
  • Data for Esperion Therapeutics' Gains from Sales and Divestitures shows a peak YoY spiked of 427.95% (in 2020) over the last 5 years.
  • Over the past 3 years, Esperion Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $3,437 in 2018, then spiked by 415.27% to $17,710 in 2019, then spiked by 427.95% to $53,587 in 2020.
  • Its Gains from Sales and Divestitures was $53,587 in Q2 2020, compared to $10,089 in Q1 2020 and $17,710 in Q4 2019.